AU2021228654A1 - Compositions and methods for treating cancer and tumor - Google Patents

Compositions and methods for treating cancer and tumor Download PDF

Info

Publication number
AU2021228654A1
AU2021228654A1 AU2021228654A AU2021228654A AU2021228654A1 AU 2021228654 A1 AU2021228654 A1 AU 2021228654A1 AU 2021228654 A AU2021228654 A AU 2021228654A AU 2021228654 A AU2021228654 A AU 2021228654A AU 2021228654 A1 AU2021228654 A1 AU 2021228654A1
Authority
AU
Australia
Prior art keywords
day
body weight
tumor
cancer
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021228654A
Other languages
English (en)
Inventor
Sin Wook Kang
Kyeongsoon KIM
Ji Hye SUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oblato Inc
Original Assignee
Oblato Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblato Inc filed Critical Oblato Inc
Publication of AU2021228654A1 publication Critical patent/AU2021228654A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021228654A 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor Abandoned AU2021228654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980645P 2020-02-24 2020-02-24
US62/980,645 2020-02-24
PCT/US2021/019457 WO2021173702A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Publications (1)

Publication Number Publication Date
AU2021228654A1 true AU2021228654A1 (en) 2022-10-13

Family

ID=77490220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021228654A Abandoned AU2021228654A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Country Status (8)

Country Link
US (1) US20230092005A1 (https=)
EP (1) EP4110315A4 (https=)
JP (1) JP2023514742A (https=)
KR (1) KR20220145861A (https=)
CN (1) CN115151250A (https=)
AU (1) AU2021228654A1 (https=)
CA (1) CA3168980A1 (https=)
WO (1) WO2021173702A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
WO2009102808A2 (en) * 2008-02-12 2009-08-20 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
AU2009288057B2 (en) * 2008-09-02 2014-07-03 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
WO2012106313A2 (en) * 2011-01-31 2012-08-09 Oklahoma Medical Research Foundation Ubiquitin interacting motif peptides as cancer therapeutics
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
KR101905864B1 (ko) * 2017-03-20 2018-10-08 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
ES3063479T3 (en) * 2017-09-20 2026-04-16 Oklahoma Med Res Found Treatment of drug resistant gliomas
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Also Published As

Publication number Publication date
CN115151250A (zh) 2022-10-04
US20230092005A1 (en) 2023-03-23
KR20220145861A (ko) 2022-10-31
WO2021173702A1 (en) 2021-09-02
JP2023514742A (ja) 2023-04-07
EP4110315A1 (en) 2023-01-04
CA3168980A1 (en) 2021-09-02
EP4110315A4 (en) 2024-03-06
WO2021173702A8 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
US20230093147A1 (en) Methods and compositions relating to improved combination therapies
US20240350439A1 (en) Calcium lactate compositions and methods of use
US8883737B2 (en) Methods of treating cancer
BRPI0808635A2 (pt) Nanopartícula compreendendo rapamicina e albumina como agente anti-câncer
JP2020505433A (ja) Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
Wang et al. Nanoparticle co-delivery of carboplatin and PF543 restores platinum sensitivity in ovarian cancer models through inhibiting platinum-induced pro-survival pathway activation
TWI849808B (zh) 藥物組成物及化療劑用於製備治療癌症之藥物的用途
US20230137776A1 (en) Use of colchicine to inhibit tumor growth and metastases
CN118139642A (zh) 治疗癌症的组合物和方法
US20230092005A1 (en) Compositions and methods for treating cancer and tumor
US20230121867A1 (en) Compositions and methods for treating diseases and conditions by depletion of mitochondrial or genomic dna from circulation
Chaudhary et al. Recent developments in the study of the microenvironment of cancer and drug delivery
US11484591B2 (en) Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20230058726A1 (en) Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
WO2021031998A1 (en) Recombinant polypeptides and uses thereof
Zhu et al. Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy
US12544366B2 (en) Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms
TWI813931B (zh) 用於癌症治療之組合及其應用
Ge Myeloid cell-based immunotherapies for the treatment of cancer
HK40118808A (zh) 全反式维甲酸脂质体及其应用於肿瘤治疗
US20210113692A1 (en) Dosing regimen
WO2024231843A1 (en) Tretinoin liposome formulations and uses thereof to treat cancer
JP2026500734A (ja) 医薬組み合わせ、及びその使用

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period